668 related articles for article (PubMed ID: 29857784)
21. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.
Sieluk J; Slejko JF; Silverman H; Perfetto E; Mullins CD
Orphanet J Rare Dis; 2020 Sep; 15(1):260. PubMed ID: 32967697
[TBL] [Abstract][Full Text] [Related]
22. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
23. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
Hong YD; Onukwugha E; Slejko JF
J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
[TBL] [Abstract][Full Text] [Related]
24. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
25. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
[TBL] [Abstract][Full Text] [Related]
27. Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus.
Bishwakarma R; Zhang W; Lin YL; Kuo YF; Cardenas VJ; Sharma G
Int J Chron Obstruct Pulmon Dis; 2018; 13():793-800. PubMed ID: 29551895
[TBL] [Abstract][Full Text] [Related]
28. Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis.
Ajmera M; Raval AD; Shen C; Sambamoorthi U
Int J Chron Obstruct Pulmon Dis; 2014; 9():339-48. PubMed ID: 24748785
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
[TBL] [Abstract][Full Text] [Related]
30. Temporal trends in healthcare utilization following primary melanoma diagnosis among Medicare beneficiaries.
Lott JP; Wang Q; Titus LJ; Onega T; Nelson HD; Weinstock MA; Elmore JG; Tosteson ANA
Br J Dermatol; 2017 Sep; 177(3):845-853. PubMed ID: 28369774
[TBL] [Abstract][Full Text] [Related]
31. Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US.
Kong AM; Pavilack M; Huo H; Shenolikar R; Moynihan M; Marchlewicz EH; Chebili-Larson C; Min S; Subramaniam DS
J Med Econ; 2021; 24(1):328-338. PubMed ID: 33576296
[TBL] [Abstract][Full Text] [Related]
32. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
[TBL] [Abstract][Full Text] [Related]
33. A Real-World Analysis of Patient Characteristics and Predictors of Hospitalization Among US Medicare Beneficiaries with Respiratory Syncytial Virus Infection.
Wyffels V; Kariburyo F; Gavart S; Fleischhackl R; Yuce H
Adv Ther; 2020 Mar; 37(3):1203-1217. PubMed ID: 32026380
[TBL] [Abstract][Full Text] [Related]
34. Cancer care spending and use by site of provider-administered chemotherapy in Medicare.
Shooshtari A; Kalidindi Y; Jung J
Am J Manag Care; 2019 Jun; 25(6):296-300. PubMed ID: 31211557
[TBL] [Abstract][Full Text] [Related]
35. Effect of coverage gap on healthcare utilization among Medicare beneficiaries with chronic obstructive pulmonary disorder.
Sansgiry SS; Bhansali A; Serna O; Kamdar M; Fleming M; Abughosh S; Stanford RH
Curr Med Res Opin; 2019 Feb; 35(2):321-328. PubMed ID: 29962241
[TBL] [Abstract][Full Text] [Related]
36. COPD is commonly underdiagnosed in patients with lung cancer: results from the RECOIL study (retrospective study of COPD infradiagnosis in lung cancer).
Parrón Collar D; Pazos Guerra M; Rodriguez P; Gotera C; Mahíllo-Fernández I; Peces-Barba G; Seijo LM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1033-1038. PubMed ID: 28408813
[TBL] [Abstract][Full Text] [Related]
37. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
38. Health care resource utilization and burden of disease in a U.S. Medicare population with a principal diagnosis of osteoarthritis of the knee.
Chen F; Su W; Bedenbaugh AV; Oruc A
J Med Econ; 2020 Oct; 23(10):1151-1158. PubMed ID: 32715848
[TBL] [Abstract][Full Text] [Related]
39. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
40. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
